Market Overview

UPDATE: Jefferies Upgrades Pfizer from Hold to Buy, Boosts Target to $38

Share:
Related PFE
$45 Billion Thursday For M&A Shows There Are Still Plenty Of Buyers Out There
Pharma Names Under Pressure Amid Perrigo Warning
Ligand Pharma Adds Tech, Grows On Partners' Success (Investor's Business Daily)

Pfizer (NYSE: PFE) has received an upgraded rating from Hold to Buy and a raised price target from $33 to $38 at Jefferies Tuesday morning.

Pfizer's upgrades follows acknowledgments that Oncology and restructuring are key themes for the Pharma sector and Pfizer has both of those covered with palbociclib looking like it could launch before year end, according to the firm's Jeffery Holland.

The Jefferies analyst expects the market to soon be reflecting incremental value in the shares based on the drivers above, adding significant upside to the companies shares.

Shares of Pfizer are up 2.7 percent to $31.42 at last check following the upgrade.

Latest Ratings for PFE

DateFirmActionFromTo
Apr 2016Goldman SachsReinstatesNeutral
Apr 2016JP MorganAssumesOverweight
Apr 2016Morgan StanleyAssumesEqual-weight

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Analyst Color News Upgrades Price Target Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!